Amplia Therapeutics has released a broad update on its clinical program for lead drug narmafotinib, headlined by a new clue from its key pancreatic cancer trial suggesting the drug's effectiveness may not depend on whether a patient's tumour carries KRAS gene mutations, which are found in more than 90 per cent of pancreatic cancers.
company
Amplia Therapeutics
Australian clinical-stage pharmaceutical company